Clinical trial · Interventional
Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer
NCT00882973CI-TRIAL-00027386completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a phase I/II trial to determine the maximum tolerated dose and recommended phase II dose of the combination therapy with Genexol-PM and gemcitabine (hereafter Genexol-PM plus gemcitabine) and to evaluate the efficacy and safety of Genexol-PM regimens (monotherapy and combination with gemcitabine) and gemcitabine monotherapy in subjects with locally advanced or metastatic pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Genexol-PM | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Cohort 1
- description
- Genexol-PM 220 mg/m2 + Gemcitabine 1,250 mg/m2
- interventionNames
- Drug: Genexol-PM
- type
- EXPERIMENTAL
- label
- Cohort 2
- description
- Genexol-PM 260 mg/m2 + Gemcitabine 1,250 mg/m2
- interventionNames
- Drug: Genexol-PM
- type
- EXPERIMENTAL
- label
- Cohort 3
- description
- Genexol-PM 300 mg/m2 + Gemcitabine 1,250 mg/m2
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Subjects who aged 18 years or older 2. Subjects whose written informed consent was obtained complying with the local regulatory requirements prior to their participation in the trial 3. Subjects who have histologically or cytologically confirmed unresectable or metastatic epithelial cancer of the exocrine pancreas. High-quality contrast-enhanced CT scanning is required to evaluate resectability. Measurable disease is not required. 4. Subjects with no other malignancy diagnosed within past five years except for: * Cured non-melanoma skin cancer * Cured cervical intraepithelial neoplasia (CIN) * Cured In-situ cervical cancer (CIS) 5. Subjects who are ECOG performance status of ≤ 1
References
Publications (0)
Data not yet available
No reference posted for this study.